Receipt date: 07/14/2006,

Sheet

MODIFIED PTO/SB/08 A & B (08-03)

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

US

Complete if Known				
Application Number	10/574,098			
Confirmation Number	Unknown			
Filing Date	March 31, 2006			
First Named Inventor	Keuk Chan BANG			
Art Unit	Unknown			
Examiner Name	Unknown			
Attorney Docket Number	Q94052			

(use as many sheets as necessary)

U.S. PATENT DOCUMENTS Document Number Examiner Cite **Publication Date** Kind Code Name of Patentee or Applicant of Cited Document Initials* No.1 MM-DD-YYYY Number (if known) US

FOREIGN PATENT DOCUMENTS							
	Cite	Foreign Patent Document		Publication Date	Name of Patentee or	T .	
	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		KR	10-580743	BI	05/09/2006	Hanni Pharm. Co., Letd.	Abstract
		wo	94/01408	Al	01/20/1994	Laboratoires Glaxo	
		WO	98/17648	Al	04/30/1998	Xenova Limited	
		wo	03/095447	Al	11/20/2003	Xenova Limited	
				1			

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
		M. Roe et al., "Reversal of P-Glycoprotein Media Multidrug Resistance by Novel Anthranilamide Derivatives", Bioorganic & Medicinal Chemistry Letters 9, (4), 1999, pp. 595-600.			
		P. Mistry et al., "In Vitro and in Vivo Reversal of P-Glycoprotein-mediated Multidrug Resistance by a Novel Potent Modulator, XR9576", Cancer Research, 61 (2), January 15, 2001.			
		A. Stewart et al., "Phase I Trial of XR9576 in Healthy Volunteers Demonstrates Modulation of P-Glycoprotein in CD56" Lymphocytes after Oral and Intravenous Administration", Clinical Cancer Research, Vol. 6, November 2000, pp. 4186-4191.			

Examiner Signature	/Zinna Davis/ (01/14/2009)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ²Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emporor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible.